Brittany Schwefel

No ORCID on file · 19 papers in corpus · active 2016-2018

Study types

  • article 18
  • rct 1

Condition tags

  • endometriosis 19
  • dysmenorrhea 5
  • dyspareunia 4
  • mesh:D004412 2
  • mesh:D004715 2
  • mesh:D017699 2
  • mesh:D004414 1
article 2018
Decreased Rescue Analgesic Use with Elagolix Treatment in Women with Endometriosis-Associated Pain [35G]
·doi:10.1097/01.aog.0000533583.86343.77

INTRODUCTION: Rescue analgesic use was evaluated in two phase 3 studies, wherein 6-months (M) of elagolix (an oral, non-peptide GnRH antagonist) treatment was associated with improved dysmenorrhea and nonmenstrual pelvic pain compared to pl…

article 2018
Elagolix reduced dyspareunia and improved health-related quality of life in premenopausal women with endometriosis-associated pain
·doi:10.1016/j.fertnstert.2018.07.249
article 2018
Elagolix Reduced Dyspareunia and Improved Health-Related Quality of Life in Premenopausal Women with Endometriosis-Associated Pain
·doi:10.1016/j.jmig.2018.09.093
article 2018
Impact of Elagolix on Health-Related Quality of Life Among Patients with Moderate to Severe Endometriosis-Associated Pain: Analysis of EQ-5D-5L Data from a Phase III Randomized Controlled Trial
·doi:10.1016/j.jval.2018.04.1014
article 2018
Long-Term Outcomes of Elagolix in Women With Endometriosis
Obstetrics and gynecology ·doi:10.1097/aog.0000000000002675

OBJECTIVE: To evaluate the efficacy and safety of elagolix, an oral, nonpeptide gonadotropin-releasing hormone antagonist, over 12 months in women with endometriosis-associated pain. METHODS: Elaris Endometriosis (EM)-III and -IV were exten…

article 2018
Long-Term Safety and Efficacy of Elagolix Treatment in Women With Endometriosis-Associated Pain [11OP]
·doi:10.1097/01.aog.0000533299.54528.7c

INTRODUCTION: Long-term safety and efficacy of elagolix, an oral, non-peptide GnRH antagonist for the management of endometriosis-associated pain, was evaluated in two 6-month (M) extension studies (Elaris EM-III and IV) of the pivotal, 6M,…

article 2018
Reductions in endometriosis-associated pain among elagolix-treated women are consistent across a range of baseline characteristics
·doi:10.1016/j.fertnstert.2018.07.254
article 2018
Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist
·doi:10.1530/ey.15.15.6

We highlight this paper for 3 reasons. First, remarkably there are few robust data on effective treatment options for endometriosis. Subcutaneous GnRH antagonists are sometimes used off-label, but with very limited evidence. Secondly, the c…

article 2017
Long-term effect of elagolix on bone mineral density: results from two phase 3 extension studies in women with endometriosis-associated pain
·doi:10.1016/j.fertnstert.2017.07.292
article 2017
Long-term safety and efficacy of elagolix treatment in women with endometriosis-associated pain: primary results from two phase 3 extension studies
·doi:10.1016/j.fertnstert.2017.07.293
article 2017
Long-Term Safety and Efficacy of Elagolix Treatment in Women with Endometriosis-Associated Pain: Primary Results From Two Phase 3 Extension Studies
·doi:10.1016/j.jmig.2017.08.078
article 2017
Maintenance of endometriosis-associated pain reduction and quality of life improvement in phase 3 extension studies with elagolix
·doi:10.1016/j.fertnstert.2017.07.294
article 2017
O-GYN-MD-126 Primary Efficacy and Safety Results from Two Double-Blind, Randomized, Placebo-Controlled Studies Of Elagolix, an Oral Gonadotropin-Releasing Hormone Antagonist, in Women With Endometriosis-Associated Pain
·doi:10.1016/j.jogc.2017.03.067
article 2017
Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist
·doi:10.1056/nejmoa1700089

Copyright © 2017 Massachusetts Medical Society. BACKGROUND Endometriosis is a chronic, estrogen-dependent condition that causes dysmenorrhea and pelvic pain. Elagolix, an oral, nonpeptide, gonadotropin-releasing hormone (GnRH) antagonist, …

rct 2017
Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist
The New England journal of medicine ·doi:10.1056/NEJMoa1700089

BACKGROUND: Endometriosis is a chronic, estrogen-dependent condition that causes dysmenorrhea and pelvic pain. Elagolix, an oral, nonpeptide, gonadotropin-releasing hormone (GnRH) antagonist, produced partial to nearly full estrogen suppres…

article 2016
Elagolix, an oral gonadotropin-releasing hormone antagonist, for the management of endometriosis-associated pain: safety and efficacy results from two double-blind, randomized, placebo-controlled studies
·doi:10.1016/j.fertnstert.2016.07.780
article 2016
The effect of elagolix on the endometrium: safety results from two randomized, placebo-controlled studies in women with endometriosis-associated pain
·doi:10.1016/j.fertnstert.2016.07.274
article 2016
The impact of elagolix on quality of life in women with endometriosis-associated pain: results from two randomized, placebo-controlled studies using the endometriosis health profile questionnaire
·doi:10.1016/j.fertnstert.2016.07.271
article 2016
Use of elagolix for the management of endometriosis-associated pain: secondary efficacy results from two randomized, placebo-controlled studies
·doi:10.1016/j.fertnstert.2016.07.774